Mizuho Starts Neumora at Outperform, Bullish on Lead Drug's Prospects
Mizuho Securities Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $20
Mizuho Securities analyst Graig Suvannavejh initiates coverage on $Neumora Therapeutics(NMRA.US)$ with a buy rating, and sets the target price at $20.According to TipRanks data, the analyst has a succ
Neumora Therapeutics Price Target Announced at $20.00/Share by Mizuho
Neumora Therapeutics Price Target Announced at $20.00/Share by Mizuho
Neumora Therapeutics Initiated at Outperform by Mizuho
Neumora Therapeutics Initiated at Outperform by Mizuho
Neumora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 95.12% Mizuho → $20 Initiates Coverage On → Outperform 03/28/2024 202.44% RBC Capital → $31 Rei
Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target
Neumora Therapeutics (NMRA) has average rating of buy and price targets ranging from $18 to $29, according to analysts polled by Capital IQ.
Express News | Neumora Therapeutics Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $20
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Express News | Neumora Therapeutics Inc: Expects to Report Topline Data From Phase 1B Study in Second Half of 2025
Express News | Neumora Therapeutics Announces Initiation of Phase 1B Study of Nmra-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
RBC Capital analyst Brian Abrahams maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 49.4
BofA Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $22
BofA Securities analyst Geoff Meacham maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 4
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Neumora Therapeutics | 10-Q: Quarterly report
Neumora Therapeutics 1Q Loss/Shr 34c >NMRA
Neumora Therapeutics 1Q Loss/Shr 34c >NMRA
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026